person · Reporting owner

Kong Garheng

Disclosed activity across 10 companies

Tapewire entity: 40892
SEC CIK: 0001435183

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALIMERA SCIENCES INCALIM · Entity 11664	Director	January 04, 2023	January 06, 2023
American Oncology Network, Inc.AONC · Entity 88884	10% owner	October 30, 2023	November 09, 2023
LABCORP HOLDINGS INC.LH · Entity 1277	Director	February 11, 2026	February 13, 2026
MELINTA THERAPEUTICS, INC. /NEW/MLNT · Entity 154249	Director	June 12, 2018	June 14, 2018
Ocugen, Inc.HSGX · Entity 5550	Director	June 15, 2018	June 19, 2018
Strongbridge Biopharma plcSBBP · Entity 131608	Director	October 05, 2021	October 06, 2021
Venus Concept Inc.VERO · Entity 55304	Director	March 24, 2023	March 28, 2023
Xeris Biopharma Holdings, Inc.XERS · Entity 4670	Director	June 04, 2026	June 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALIMERA SCIENCES INC

Report date January 04, 2023 · Filed January 06, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.72 · Expires 2033-01-03	Direct	6,000	Reported balance After 2023-01-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-04 · Grant · Acquired 6,000 · Balance 6,000 F1: Vests in full on the date of the Issuer's annual meeting of stockholders in 2023 or any special meeting held in lieu thereof, provided the Reporting Person provides continuous service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Vests in full on the date of the Issuer's annual meeting of stockholders in 2023 or any special meeting held in lieu thereof, provided the Reporting Person provides continuous service to the Issuer through such date.

American Oncology Network, Inc.

Report date October 30, 2023 · Filed November 09, 2023

Jointly reported with HealthQuest Tactical Opportunities Fund, L.P., HealthQuest TOF Management, L.L.C.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series A Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $10.00	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-10-30 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: Each share of the Series A Preferred Stock is convertible into shares of Class A Common Stock of the Issuer at any time, at the Reporting Person's election. The number of shares of the Issuer's Class A Common Stock received upon conversion of a share of Series A Preferred Stock equals the quotient of (A) the sum of (i) the original issue price of $10.00, as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after September 20, 2023, and (ii) any accrued and unpaid dividends on such share, divided by (B) an initial conversion price of $10.00, which is subject to certain anti-dilution adjustments. The Series A Preferred Stock is perpetual and therefore has no expiration date. F2: The shares are held directly by HealthQuest Tactical Opportunities Fund, L.P. ("HealthQuest Tactical Opportunities"). HealthQuest TOF Management, L.L.C. ("HealthQuest TOF Management") is HealthQuest Tactical Opportunities' general partner, and Dr. Garheng Kong is HealthQuest TOF Management's managing member. HealthQuest TOF Management and Dr. Kong may be deemed to have sole voting and dispositive power over the shares held by HealthQuest Tactical Opportunities. HealthQuest TOF Management and Dr. Kong disclaim beneficial ownership of all shares of common stock owned by HealthQuest Tactical Opportunities except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the Series A Preferred Stock is convertible into shares of Class A Common Stock of the Issuer at any time, at the Reporting Person's election. The number of shares of the Issuer's Class A Common Stock received upon conversion of a share of Series A Preferred Stock equals the quotient of (A) the sum of (i) the original issue price of $10.00, as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after September 20, 2023, and (ii) any accrued and unpaid dividends on such share, divided by (B) an initial conversion price of $10.00, which is subject to certain anti-dilution adjustments. The Series A Preferred Stock is perpetual and therefore has no expiration date.

F2: The shares are held directly by HealthQuest Tactical Opportunities Fund, L.P. ("HealthQuest Tactical Opportunities"). HealthQuest TOF Management, L.L.C. ("HealthQuest TOF Management") is HealthQuest Tactical Opportunities' general partner, and Dr. Garheng Kong is HealthQuest TOF Management's managing member. HealthQuest TOF Management and Dr. Kong may be deemed to have sole voting and dispositive power over the shares held by HealthQuest Tactical Opportunities. HealthQuest TOF Management and Dr. Kong disclaim beneficial ownership of all shares of common stock owned by HealthQuest Tactical Opportunities except to the extent of any pecuniary interest therein.

LABCORP HOLDINGS INC.

Report date February 11, 2026 · Filed February 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,739	Reported balance After 2026-02-11 transaction · row 1 1 source row Row 1 · 2026-02-11 · Exercise / conversion · Acquired 897 · Balance 13,739 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	773	Reported balance After 2026-02-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-11 · Exercise / conversion · Disposed 897 · Balance 773 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2: The Restricted Stock Units vested fully on February 11, 2026. F3: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

F2: The Restricted Stock Units vested fully on February 11, 2026.

F3: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

MELINTA THERAPEUTICS, INC. /NEW/

Report date June 12, 2018 · Filed June 14, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.45 · Expires 2028-04-20	Direct	25,000	Reported balance After 2018-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-12 · Grant · Acquired 25,000 · Balance 25,000 F1: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. F2: One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.45 · Expires 2028-04-20	Direct	9,100	Reported balance After 2018-06-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-12 · Grant · Acquired 9,100 · Balance 9,100 F1: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018.

F2: One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019.

Ocugen, Inc.

Report date June 15, 2018 · Filed June 19, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2028-06-14	Direct	25,000	Reported balance After 2018-06-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-15 · Grant · Acquired 25,000 · Balance 25,000 F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018.

Strongbridge Biopharma plc

Report date October 05, 2021 · Filed October 06, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	0	Reported balance After 2021-10-05 transaction · row 1 1 source row Row 1 · 2021-10-05 · Disposition to issuer · Disposed 63,993 · Balance 0 F1: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-10-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-10-05 · Disposition to issuer · Disposed 154,385 · Balance 0 F2: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

Filing footnotes · ownership attribution and instrument terms

F1: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.

F2: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

Venus Concept Inc.

Report date March 24, 2023 · Filed March 28, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.19 · Expires 2033-03-24	Direct	75,000	Reported balance After 2023-03-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-03-24 · Grant · Acquired 75,000 · Balance 75,000 F1: The options vest with respect to 1/16th of the underlying Common Stock on each quarterly anniversary of the date of grant, subject to continued service through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest with respect to 1/16th of the underlying Common Stock on each quarterly anniversary of the date of grant, subject to continued service through each applicable vesting date.

Xeris Biopharma Holdings, Inc.

Report date June 04, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	238,337	Reported balance After 2026-06-04 transaction · row 1 1 source row Row 1 · 2026-06-04 · Grant · Acquired 24,193 · Balance 238,337 F1: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.15 · Expires 2036-06-04	Direct	32,996	Reported balance After 2026-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-04 · Grant · Acquired 32,996 · Balance 32,996 F2: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

F2: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AVEDRO INC

Report date November 21, 2019 · Filed November 26, 2019

Section 16 reporting ended · disclosed 2019-11-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2019-11-21 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-11-21 · Disposition to issuer · Disposed 1,437,096 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F2: The shares are directly held by HealthQuest Partners II, L.P. ("HealthQuest"). HealthQuest Venture Management II, L.L.C. ("HealthQuest Management") is the general partner of HealthQuest. HealthQuest Management may be deemed to have voting and dispositive power over the shares held by HealthQuest. The Reporting Person is the managing member of HealthQuest Management and disclaims beneficial interest over all of the shares held by HealthQuest except to the extent of his pecuniary interest therein.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2029-01-08	Direct	Reported balance After 2019-11-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-21 · Disposition to issuer · Disposed 8,314 · Balance 0 F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-11-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-21 · Disposition to issuer · Disposed 3,005 · Balance 0 F4: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share.

F2: The shares are directly held by HealthQuest Partners II, L.P. ("HealthQuest"). HealthQuest Venture Management II, L.L.C. ("HealthQuest Management") is the general partner of HealthQuest. HealthQuest Management may be deemed to have voting and dispositive power over the shares held by HealthQuest. The Reporting Person is the managing member of HealthQuest Management and disclaims beneficial interest over all of the shares held by HealthQuest except to the extent of his pecuniary interest therein.

F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer.

F4: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F5: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU.

CASTLE BIOSCIENCES INC

Report date May 12, 2020 · Filed May 19, 2020 · Amendment

Jointly reported with Sofinnova HealthQuest Partners, L.P., HealthQuest Venture Management, L.L.C.

Section 16 reporting ended · disclosed 2020-05-19. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,433,577	Last balance in matching sequence After 2020-05-12 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2020-05-12 · Sale · Disposed 50,000 · Balance 1,633,577 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Healthquest Partners, L.P. on December 17, 2019. F2: Represents the weighted-average sale price per share of a series of transactions, all of which were executed on May 12, 2020. The actual sale prices ranged from a low of $33.034 to a high of $33.04, inclusive. Each Reporting Person undertakes to provide upon request of the SEC Staff, Castle Biosciences, Inc. or a Castle Biosciences, Inc. security holder full information regarding the number of shares sold at each price within the range. F3: The shares are directly held by Sofinnova HealthQuest Partners, L.P. ("HealthQuest"). HealthQuest Venture Management, L.L.C. ("HQVM"), the general partner of HealthQuest, and Garheng Kong, the managing member of HQVM, may be deemed to have sole voting and dispositive power with respect to the shares held of record by HealthQuest. Mr. Kong and HQVM disclaim beneficial ownership over all shares owned by HealthQuest except to the extent of any pecuniary interest therein. Row 2 · 2020-05-12 · Sale · Disposed 100,000 · Balance 1,533,577 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Healthquest Partners, L.P. on December 17, 2019. F4: Represents the weighted-average sale price per share of a series of transactions, all of which were executed on May 12, 2020. The actual sale prices ranged from a low of $34.0861 to a high of $34.6399, inclusive. Each Reporting Person undertakes to provide upon request of the SEC Staff, Castle Biosciences, Inc. or a Castle Biosciences, Inc. security holder full information regarding the number of shares sold at each price within the range. F3: The shares are directly held by Sofinnova HealthQuest Partners, L.P. ("HealthQuest"). HealthQuest Venture Management, L.L.C. ("HQVM"), the general partner of HealthQuest, and Garheng Kong, the managing member of HQVM, may be deemed to have sole voting and dispositive power with respect to the shares held of record by HealthQuest. Mr. Kong and HQVM disclaim beneficial ownership over all shares owned by HealthQuest except to the extent of any pecuniary interest therein. Row 3 · 2020-05-12 · Sale · Disposed 100,000 · Balance 1,433,577 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Healthquest Partners, L.P. on December 17, 2019. F5: Represents the weighted-average sale price per share of a series of transactions, all of which were executed on May 12, 2020. The actual sale prices ranged from a low of $35.175 to a high of $35.665, inclusive. Each Reporting Person undertakes to provide upon request of the SEC Staff, Castle Biosciences, Inc. or a Castle Biosciences, Inc. security holder full information regarding the number of shares sold at each price within the range. F3: The shares are directly held by Sofinnova HealthQuest Partners, L.P. ("HealthQuest"). HealthQuest Venture Management, L.L.C. ("HQVM"), the general partner of HealthQuest, and Garheng Kong, the managing member of HQVM, may be deemed to have sole voting and dispositive power with respect to the shares held of record by HealthQuest. Mr. Kong and HQVM disclaim beneficial ownership over all shares owned by HealthQuest except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Healthquest Partners, L.P. on December 17, 2019.

F2: Represents the weighted-average sale price per share of a series of transactions, all of which were executed on May 12, 2020. The actual sale prices ranged from a low of $33.034 to a high of $33.04, inclusive. Each Reporting Person undertakes to provide upon request of the SEC Staff, Castle Biosciences, Inc. or a Castle Biosciences, Inc. security holder full information regarding the number of shares sold at each price within the range.

F3: The shares are directly held by Sofinnova HealthQuest Partners, L.P. ("HealthQuest"). HealthQuest Venture Management, L.L.C. ("HQVM"), the general partner of HealthQuest, and Garheng Kong, the managing member of HQVM, may be deemed to have sole voting and dispositive power with respect to the shares held of record by HealthQuest. Mr. Kong and HQVM disclaim beneficial ownership over all shares owned by HealthQuest except to the extent of any pecuniary interest therein.

F4: Represents the weighted-average sale price per share of a series of transactions, all of which were executed on May 12, 2020. The actual sale prices ranged from a low of $34.0861 to a high of $34.6399, inclusive. Each Reporting Person undertakes to provide upon request of the SEC Staff, Castle Biosciences, Inc. or a Castle Biosciences, Inc. security holder full information regarding the number of shares sold at each price within the range.

F5: Represents the weighted-average sale price per share of a series of transactions, all of which were executed on May 12, 2020. The actual sale prices ranged from a low of $35.175 to a high of $35.665, inclusive. Each Reporting Person undertakes to provide upon request of the SEC Staff, Castle Biosciences, Inc. or a Castle Biosciences, Inc. security holder full information regarding the number of shares sold at each price within the range.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 04, 2026 Filed Jun 5, 2026 22:39 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	32,996	$6.15 Strike: $6.15	$202,925.40	Disclosure SEC source: 0001867096-26-000041 · wk-form4_1780699173.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,996 Underlying: Common Stock · 32,996 shares Expires 2036-06-04 F2 · derivative.exercise_date: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. Read SEC document
June 04, 2026 Filed Jun 5, 2026 22:39 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantCommon Stock	24,193	$0.00	$0.00	Disclosure SEC source: 0001867096-26-000041 · wk-form4_1780699173.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,337 F1 · shares: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. Read SEC document
February 11, 2026 Filed Feb 13, 2026 17:53 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionRestricted Stock Unit · Derivative	897	$0.00	$0.00	Disclosure SEC source: 0000920148-26-000074 · form4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 773 Underlying: Common Stock · 897 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2026. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document
February 11, 2026 Filed Feb 13, 2026 17:53 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionCommon Stock	897	Not disclosed	Not disclosed	Disclosure SEC source: 0000920148-26-000074 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document
February 10, 2026 Filed Feb 12, 2026 16:28 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	GrantRestricted Stock Unit · Derivative	773	$0.00	$0.00	Disclosure SEC source: 0000920148-26-000059 · form4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,670 Underlying: Common Stock · 773 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 10, 2027. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 10, 2027. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document
June 04, 2025 Filed Jun 4, 2025 22:59 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001867096-25-000106 · wk-form4_1749077962.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,144 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders. Read SEC document
February 11, 2025 Filed Feb 13, 2025 13:23 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	GrantRestricted Stock Unit · Derivative	897	$0.00	$0.00	Disclosure SEC source: 0001127602-25-004517 · form4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897 Underlying: Common Stock · 897 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2026. Read SEC document
February 06, 2025 Filed Feb 10, 2025 13:52 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionRestricted Stock Unit · Derivative	944	$0.00	$0.00	Disclosure SEC source: 0001127602-25-003707 · form4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 944 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. ("LHI") Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 6, 2025. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 6, 2025. Read SEC document
February 06, 2025 Filed Feb 10, 2025 13:52 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionCommon Stock	944	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-25-003707 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. ("LHI") Common Stock. Read SEC document
June 05, 2024 Filed Jun 5, 2024 20:18 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001867096-24-000104 · wk-form4_1717618697.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,144 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 5, 2025 or the date of the Company's next annual meeting of stockholders. Read SEC document
March 15, 2024 Filed Apr 1, 2024 21:45 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	OtherCommon Stock	6,474	Not disclosed	Not disclosed	Disclosure SEC source: 0001867096-24-000041 · wk-form4_1712007900.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,144 F1 · kind: Keveyis Sales 2023 Milestone achieved resulting in the settlement of the related Contingent Value Right ("CVR") in shares of Xeris Biopharma Holdings, Inc. (the "Company")'s Common Stock. F2 · shares: The reporting person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on October 5, 2021, the effective time of the Merger (as defined below), pursuant to the transaction agreement dated as of May 24, 2021 by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), where HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge, and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger"). F3 · price: The number of shares of Common Stock for the CVR is equal to the product (A) $0.25 divided by the volume weighted average price for the Company's Common Stock as reported by Nasdaq for the ten (10) Trading Days immediately prior to October 5, 2021 and (B) the number of CVRs held by the holder as reflected on the CVR Register. Read SEC document
February 07, 2024 Filed Feb 8, 2024 17:47 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionRestricted Stock Unit · Derivative	947	$0.00	$0.00	Disclosure SEC source: 0001127602-24-003889 · form4.xml · derivative · entry 3 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document
February 07, 2024 Filed Feb 8, 2024 17:47 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionCommon Stock	947	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-003889 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document
February 06, 2024 Filed Feb 8, 2024 17:47 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	GrantRestricted Stock Unit · Derivative	944	$0.00	$0.00	Disclosure SEC source: 0001127602-24-003889 · form4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,891 Underlying: Common Stock · 944 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document
June 07, 2023 Filed Jun 7, 2023 21:00 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantCommon Stock	42,500	$0.00	$0.00	Disclosure SEC source: 0001867096-23-000101 · wk-form4_1686171645.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,670 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 7, 2024 or the date of the Company's next annual meeting of stockholders. Read SEC document
March 24, 2023 Filed Mar 28, 2023 21:59 UTC	Venus Concept Inc. VERO · Entity 55304	GrantEmployee Stock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $0.19	$0.00	Disclosure SEC source: 0001362118-23-000021 · primary_doc.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-03-24 F1 · derivative.exercise_date: The options vest with respect to 1/16th of the underlying Common Stock on each quarterly anniversary of the date of grant, subject to continued service through each applicable vesting date. Read SEC document
February 11, 2023 Filed Feb 14, 2023 20:15 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionRestricted Stock Unit · Derivative	742	$0.00	$0.00	Disclosure SEC source: 0001127602-23-005110 · form4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document
February 11, 2023 Filed Feb 14, 2023 20:15 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionCommon Stock	742	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-005110 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document
February 07, 2023 Filed Feb 9, 2023 17:34 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	GrantRestricted Stock Unit · Derivative	849	$0.00	$0.00	Disclosure SEC source: 0001127602-23-004134 · form4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,591 Underlying: Common Stock · 849 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 7, 2024. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 7, 2024. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document
January 04, 2023 Filed Jan 6, 2023 21:55 UTC	ALIMERA SCIENCES INC ALIM · Entity 11664	GrantStock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $2.72	$0.00	Disclosure SEC source: 0001474506-23-000008 · primary_doc.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: Vests in full on the date of the Issuer's annual meeting of stockholders in 2023 or any special meeting held in lieu thereof, provided the Reporting Person provides continuous service to the Issuer through such date. Read SEC document
November 18, 2022 Filed Nov 22, 2022 22:14 UTC	Venus Concept Inc. VERO · Entity 55304	PurchaseVoting Convertible Preferred Stock · Derivative	335,000	$2.00 Strike: $0.00	$670,000.00	Disclosure SEC source: 0001567619-22-020788 · doc1.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · HealthQuest Partners II, L.P. Disclosed balance after: 335,000 Underlying: Common Stock · 3,350,000 shares Expires not disclosed F1 · derivative.exercise_price: The Voting Preferred Stock will convert into shares of Common Stock on a one for ten basis (i) at the option the holder or (ii) at the option of the Company within 30 days following the occurrence of certain events. The Voting Preferred Stock votes with the Common Stock on an as-converted basis. The Voting Preferred Stock does not expire. F1 · derivative.expiration_date: The Voting Preferred Stock will convert into shares of Common Stock on a one for ten basis (i) at the option the holder or (ii) at the option of the Company within 30 days following the occurrence of certain events. The Voting Preferred Stock votes with the Common Stock on an as-converted basis. The Voting Preferred Stock does not expire. F2 · ownership.nature: The shares were purchased by HealthQuest Partners II, L.P. ("HealthQuest"). HealthQuest Venture Management II, L.L.C. ("HQVM II"), the general partner of HealthQuest, and Garheng Kong, the managing member of HQVM II, may be deemed to have sole voting and dispositive power with respect to the shares held of record by HealthQuest. The Reporting Person and HQVM II disclaim beneficial ownership of all shares held by HealthQuest except to the extent of any pecuniary interest therein. Read SEC document
June 08, 2022 Filed Jun 9, 2022 23:05 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $2.10	$0.00	Disclosure SEC source: 0001867096-22-000097 · wf-form4_165481592522339.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-08 F2 · derivative.exercise_date: Such options will vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders. Read SEC document
June 08, 2022 Filed Jun 9, 2022 23:05 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantCommon Stock	15,000	$0.00	$0.00	Disclosure SEC source: 0001867096-22-000097 · wf-form4_165481592522339.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,170 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders. Read SEC document
March 25, 2022 Filed Mar 28, 2022 17:25 UTC	Venus Concept Inc. VERO · Entity 55304	GrantEmployee Stock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $1.38	$0.00	Disclosure SEC source: 0001362118-22-000029 · primary_doc.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2032-03-25 F1 · derivative.exercise_date: The option vests with respect to 1/16th of the underlying Common Stock on each quarterly anniversary of the date of grant, subject to continued service through each applicable vesting date. Read SEC document
February 11, 2022 Filed Feb 15, 2022 17:32 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	GrantRestricted Stock Unit · Derivative	742	$0.00	$0.00	Disclosure SEC source: 0001127602-22-004955 · form4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2023. Read SEC document
February 02, 2022 Filed Feb 4, 2022 14:05 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionRestricted Stock Unit · Derivative	771	$0.00	$0.00	Disclosure SEC source: 0001127602-22-003269 · form4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 2, 2022. Read SEC document
February 02, 2022 Filed Feb 4, 2022 14:05 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionCommon Stock	771	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-003269 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document
December 15, 2021 Filed Dec 17, 2021 21:15 UTC	Venus Concept Inc. VERO · Entity 55304	PurchaseCommon Shares	1,600,000	$1.25	$2,000,000.00	Disclosure SEC source: 0001567619-21-022249 · doc1.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by HealthQuest Partners II, L.P. Disclosed balance after: 6,795,621 F1 · ownership.nature: The shares were purchased by HealthQuest Partners II, L.P. ("HealthQuest"). HealthQuest Venture Management II, L.L.C. ("HQVM II"), the general partner of HealthQuest, and Garheng Kong, the managing member of HQVM II, may be deemed to have sole voting and dispositive power with respect to the shares held of record by HealthQuest. The Reporting Person and HQVM II disclaim beneficial ownership of all shares held by HealthQuest except to the extent of any pecuniary interest therein. Read SEC document
November 02, 2021 Filed Nov 5, 2021 01:09 UTC	ALIMERA SCIENCES INC ALIM · Entity 11664	GrantStock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $4.05	$0.00	Disclosure SEC source: 0001474506-21-000164 · primary_doc.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-11-01 F1 · derivative.exercise_date: Vests in full on June 15, 2022, provided the Reporting Person provides continuous service to the Issuer through such date. Read SEC document
October 05, 2021 Filed Oct 5, 2021 23:53 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	31,360	Not disclosed Strike: $9.89	Not disclosed	Disclosure SEC source: 0000899243-21-039342 · doc4.xml · derivative · entry 6 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,360 Underlying: Common Stock · 31,360 shares Expires 2028-05-15 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document
October 05, 2021 Filed Oct 5, 2021 23:53 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	31,360	Not disclosed Strike: $5.62	Not disclosed	Disclosure SEC source: 0000899243-21-039342 · doc4.xml · derivative · entry 5 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,360 Underlying: Common Stock · 31,360 shares Expires 2027-05-11 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document
October 05, 2021 Filed Oct 5, 2021 23:53 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	31,360	Not disclosed Strike: $7.02	Not disclosed	Disclosure SEC source: 0000899243-21-039342 · doc4.xml · derivative · entry 4 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,360 Underlying: Common Stock · 31,360 shares Expires 2026-05-12 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document
October 05, 2021 Filed Oct 5, 2021 23:53 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	7,357	Not disclosed Strike: $22.39	Not disclosed	Disclosure SEC source: 0000899243-21-039342 · doc4.xml · derivative · entry 3 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,357 Underlying: Common Stock · 7,357 shares Expires 2025-10-16 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document
October 05, 2021 Filed Oct 5, 2021 23:53 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	19,600	Not disclosed Strike: $22.39	Not disclosed	Disclosure SEC source: 0000899243-21-039342 · doc4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,600 Underlying: Common Stock · 19,600 shares Expires 2025-10-16 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document
October 05, 2021 Filed Oct 5, 2021 23:53 UTC	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantCommon Stock	50,170	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-039342 · doc4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,170 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis. Read SEC document
October 05, 2021 Filed Oct 6, 2021 23:41 UTC	Strongbridge Biopharma plc SBBP · Entity 131608	Disposition to issuerStock Option (Right to Buy) · Derivative	154,385	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-21-009278 · edgar.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 154,385 shares Expires not disclosed F2 · derivative.exercise_price: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option. F2 · price: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option. F2 · derivative.exercise_date: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option. F2 · derivative.expiration_date: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option. Read SEC document
October 05, 2021 Filed Oct 6, 2021 23:41 UTC	Strongbridge Biopharma plc SBBP · Entity 131608	Disposition to issuerOrdinary Shares	63,993	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-21-009278 · edgar.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election. F1 · price: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election. Read SEC document
October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	19,650	$2.37 Strike: $2.37	$46,570.50	Disclosure SEC source: 0000899243-21-039750 · doc4a.xml · derivative · entry 7 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,650 Underlying: Common Stock · 19,650 shares Expires 2031-10-05 F4 · derivative.exercise_date: One third of these options shall vest in equal annual installments until the third anniversary of the date of grant. Read SEC document
October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	31,360	Not disclosed Strike: $9.89	Not disclosed	Disclosure SEC source: 0000899243-21-039750 · doc4a.xml · derivative · entry 6 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,360 Underlying: Common Stock · 31,360 shares Expires 2028-05-15 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document
October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	31,360	Not disclosed Strike: $5.62	Not disclosed	Disclosure SEC source: 0000899243-21-039750 · doc4a.xml · derivative · entry 5 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,360 Underlying: Common Stock · 31,360 shares Expires 2027-05-11 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document
October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	31,360	Not disclosed Strike: $7.02	Not disclosed	Disclosure SEC source: 0000899243-21-039750 · doc4a.xml · derivative · entry 4 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,360 Underlying: Common Stock · 31,360 shares Expires 2026-05-12 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document
October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	7,357	Not disclosed Strike: $22.39	Not disclosed	Disclosure SEC source: 0000899243-21-039750 · doc4a.xml · derivative · entry 3 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,357 Underlying: Common Stock · 7,357 shares Expires 2025-10-16 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document
October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantStock Option (Right to Buy) · Derivative	19,600	Not disclosed Strike: $22.39	Not disclosed	Disclosure SEC source: 0000899243-21-039750 · doc4a.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,600 Underlying: Common Stock · 19,600 shares Expires 2025-10-16 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document
October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment	Xeris Biopharma Holdings, Inc. XERS · Entity 4670	GrantCommon Stock	50,170	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-039750 · doc4a.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,170 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis. Read SEC document
October 01, 2021 Filed Oct 5, 2021 23:22 UTC	Strongbridge Biopharma plc SBBP · Entity 131608	Tax withholdingOrdinary Shares	17,763	$2.06	$36,591.78	Disclosure SEC source: 0001179110-21-009219 · edgar.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,993 F1 · shares: Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units. Read SEC document
May 18, 2021 Filed May 18, 2021 23:11 UTC	Strongbridge Biopharma plc SBBP · Entity 131608	GrantOrdinary Shares	40,000	$0.00	$0.00	Disclosure SEC source: 0001179110-21-005556 · edgar.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,756 F1 · shares: Represents a grant of restricted stock units, which vest in full on May 18, 2022, provided that the Reporting Person continues to serve as a member of the board of directors of the Issuer through that date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 14, 2021 Filed May 17, 2021 23:27 UTC	Strongbridge Biopharma plc SBBP · Entity 131608	Tax withholdingOrdinary Shares	19,200	$2.35	$45,120.00	Disclosure SEC source: 0001179110-21-005450 · edgar.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,756 F1 · shares: Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units. Read SEC document
March 26, 2021 Filed Mar 31, 2021 01:47 UTC	Venus Concept Inc. VERO · Entity 55304	GrantDirector Stock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $2.37	$0.00	Disclosure SEC source: 0001567619-21-007259 · doc1.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-03-26 F1 · derivative.exercise_date: The options vest with respect to 1/16th of the underlying Common Stock on each quarterly anniversary of the date of grant, subject to continued service through each applicable vesting date. Read SEC document
February 04, 2021 Filed Feb 8, 2021 19:57 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionRestricted Stock Unit · Derivative	986	$0.00	$0.00	Disclosure SEC source: 0001127602-21-004331 · form4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 Underlying: Common Stock · 986 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document
February 04, 2021 Filed Feb 8, 2021 19:57 UTC	LABCORP HOLDINGS INC. LH · Entity 1277	Exercise / conversionCommon Stock	986	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-21-004331 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.